Compare EFC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFC | NRIX |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | 400 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2020 |
| Metric | EFC | NRIX |
|---|---|---|
| Price | $11.97 | $15.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $14.55 | ★ $29.46 |
| AVG Volume (30 Days) | ★ 1.6M | 722.8K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 13.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.40 | $26.32 |
| P/E Ratio | $9.50 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $11.12 | $8.18 |
| 52 Week High | $14.12 | $22.50 |
| Indicator | EFC | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 43.85 |
| Support Level | $11.57 | $14.91 |
| Resistance Level | $14.00 | $16.47 |
| Average True Range (ATR) | 0.27 | 0.79 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 36.12 | 42.59 |
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.